A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Young Volunteers
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2017
At a glance
- Drugs NGP 555 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors NeuroGenetic Pharmaceuticals
- 09 Jan 2017 Results published in the NeuroGenetic Pharmaceuticals Media Release
- 12 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Aug 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.